These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10937726)

  • 1. Production and application of LPA polyclonal antibody.
    Chen JH; Zou F; Wang ND; Xie SW; Zhang X
    Bioorg Med Chem Lett; 2000 Aug; 10(15):1691-3. PubMed ID: 10937726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum lysophosphatidic acid concentrations measured by dot immunogold filtration assay in patients with acute myocardial infarction.
    Chen X; Yang XY; Wang ND; Ding C; Yang YJ; You ZJ; Su Q; Chen JH
    Scand J Clin Lab Invest; 2003; 63(7-8):497-503. PubMed ID: 14743959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysophosphatidic acid (LPA)-antibody (504B3) engagement detected by interferometry identifies off-target binding.
    Ray M; Kihara Y; Bornhop DJ; Chun J
    Lipids Health Dis; 2021 Apr; 20(1):32. PubMed ID: 33853612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of plasma lysophosphatidic acid levels in ovarian cancer patients: A case-control study and updated meta-analysis.
    Cao L; Zhang Y; Fu Z; Dong L; Yang S; Meng W; Li Y; Zhang W; Zhang J; Zheng C; Zhu H; Fan L
    J Obstet Gynaecol Res; 2015 Dec; 41(12):1951-8. PubMed ID: 26472266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer.
    Zhang YJ; Cao LY; Fu ZZ; Wang YJ; Wang GX; Gu T
    J Cancer Res Ther; 2015; 11(2):375-80. PubMed ID: 26148603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2).
    So J; Wang FQ; Navari J; Schreher J; Fishman DA
    Gynecol Oncol; 2005 Jun; 97(3):870-8. PubMed ID: 15919106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Characterization of a Dual-Protein Strategy for an Early-Stage Assay of Ovarian Cancer Biomarker Lysophosphatidic Acid.
    Davoudian K; Spagnolo S; Lotay N; Satkauskas M; Mészáros G; Hianik T; Keresztes Z; Walker G; Thompson M
    Biosensors (Basel); 2024 Jun; 14(6):. PubMed ID: 38920591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical detection of lysophosphatidic acid: A new window for ovarian cancer diagnostics.
    Huang X; Feng B; Liu M; Liu Z; Li S; Zeng W
    Talanta; 2022 Sep; 247():123561. PubMed ID: 35609485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lysophosphatidic acid in ovarian cancer patients].
    Sedlákova I; Vávrová J; Tosner J; Hanousek L
    Ceska Gynekol; 2006 Jul; 71(4):312-7. PubMed ID: 16956044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of lysophosphatidic acid receptor in human ovarian cancer cell lines 3AO, SKOV3, OVCAR3 and its significance].
    Wang P; Wu XH; Chen WX; Shan BE; Guo Q
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Nov; 25(11):1422-4, 1431. PubMed ID: 16305971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8.
    So J; Navari J; Wang FQ; Fishman DA
    Gynecol Oncol; 2004 Nov; 95(2):314-22. PubMed ID: 15491751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysophosphatidic acid inhibits anti-Fas-mediated apoptosis enhanced by actin depolymerization in epithelial ovarian cancer.
    Meng Y; Kang S; Fishman DA
    FEBS Lett; 2005 Feb; 579(5):1311-9. PubMed ID: 15710431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lysophosphatidic acid (LPA) stimulates invasion and metastatic colonization of ovarian cancer cells through Rac activation].
    Yu X; Zhang Y; Chen H
    Zhonghua Zhong Liu Za Zhi; 2015 Feb; 37(2):95-100. PubMed ID: 25975684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of total plasma lysophosphatidic acid in ovarian cancer: a meta-analysis.
    Lu Z; Chen Y; Hu Z; Hu C
    Int J Gynecol Cancer; 2015 Jan; 25(1):18-23. PubMed ID: 25398018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysophospholipids activate ovarian and breast cancer cells.
    Xu Y; Fang XJ; Casey G; Mills GB
    Biochem J; 1995 Aug; 309 ( Pt 3)(Pt 3):933-40. PubMed ID: 7639713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surface-enhanced Raman scattering detection of lysophosphatidic acid.
    Seballos L; Zhang JZ; Sutphen R
    Anal Bioanal Chem; 2005 Nov; 383(5):763-7. PubMed ID: 16261318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysophosphatidic acid signaling in ovarian cancer.
    Jesionowska A; Cecerska-Heryc E; Matoszka N; Dolegowska B
    J Recept Signal Transduct Res; 2015; 35(6):578-84. PubMed ID: 26393967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses.
    Xiao Y; Chen Y; Kennedy AW; Belinson J; Xu Y
    Ann N Y Acad Sci; 2000 Apr; 905():242-59. PubMed ID: 10818458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer.
    Meleh M; Pozlep B; Mlakar A; Meden-Vrtovec H; Zupancic-Kralj L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 858(1-2):287-91. PubMed ID: 17766199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer.
    Lee Z; Swaby RF; Liang Y; Yu S; Liu S; Lu KH; Bast RC; Mills GB; Fang X
    Cancer Res; 2006 Mar; 66(5):2740-8. PubMed ID: 16510595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.